ReviewPharmacoEconomics1996
An historical survey of UK government measures to control the NHS medicines expenditure from 1948 to 1996.
Review in PharmacoEconomics, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pharmaceutical policies: effects of financial incentives for prescribers.The Cochrane database of systematic reviews · 2015Pooled it
- Pharmaceutical policy regarding generic drugs in Belgium.PharmacoEconomics · 2005Article
- Pharmaceutical price regulation. A study on the impact of the rate-of-return regulation in the UK.PharmacoEconomics · 1999Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since the inception of the National Health Service in 1948, successive British governments have taken various measures to restrain the growth of the medicines bill. A total of 10 different measures have been introduced with very limited success. The most effective measures have been those directed at increasing the level of generic prescribing; such measures mean that the patient is treated with older, off-patent medicines which, although cheap, are not necessarily cost effective or the most clinically effective. Possible future directions for curtailing expenditure include controlling the price of off-patent branded medicines to the level of generic products, and the initiation of a government policy to actively encourage prescribing of newer medicines where these are shown to be more clinically effective or more cost effective.
Indexed as
Identifiers
10163570What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.